Literature DB >> 31848779

Cannabinoids and dystonia: an issue yet to be defined.

Marcello Mario Mascia1, Daniele Carmagnini2, Giovanni Defazio2.   

Abstract

Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal movements and postures. Besides motor manifestations, patients with dystonia also display non-motor signs and symptoms including psychiatric and sensory disturbances. Symptomatic treatment of motor signs in dystonia largely relies on intramuscular botulinum toxin injections and, in selected cases, on deep brain stimulation. Oral medications and physical therapy offer a few benefits only in a minority of patients. Cannabinoids have been shown to be a complementary treatment in several neurological disorders but their usefulness in dystonia have not been systematically assessed. Given recent policy changes in favor of cannabis use in clinical practice and the request for alternative treatments, it is important to understand how cannabinoids may impact people with dystonia. Reviewing the evidence so far available and our own experience, cannabinoids seem to be effective in single cases but further studies are required to improve our understanding on their role as complementary treatment in dystonia.

Entities:  

Keywords:  Cannabinoids; Dystonia

Year:  2019        PMID: 31848779     DOI: 10.1007/s10072-019-04196-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  29 in total

1.  Development and validation of a clinical scale for rating the severity of blepharospasm.

Authors:  Giovanni Defazio; Mark Hallett; Hyder A Jinnah; Glenn T Stebbins; Angelo F Gigante; Gina Ferrazzano; Antonella Conte; Giovanni Fabbrini; Alfredo Berardelli
Journal:  Mov Disord       Date:  2015-04       Impact factor: 10.338

2.  Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  Stephen Wright; Vijayshree Yadav; Christopher Bever; James Bowen; Allen Bowling; Bianca Weinstock-Guttman; Michelle Cameron; Dennis Bourdette; Gary S Gronseth; Pushpa Narayanaswami
Journal:  Neurology       Date:  2014-10-14       Impact factor: 9.910

3.  Remission in dystonia - Systematic review of the literature and meta-analysis.

Authors:  Tina Mainka; Roberto Erro; John Rothwell; Andrea A Kühn; Kailash P Bhatia; Christos Ganos
Journal:  Parkinsonism Relat Disord       Date:  2019-02-16       Impact factor: 4.891

Review 4.  Cannabinoids and Pain: Sites and Mechanisms of Action.

Authors:  Katarzyna Starowicz; David P Finn
Journal:  Adv Pharmacol       Date:  2017-06-20

Review 5.  Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

Authors:  Concepción García; Cristina Palomo-Garo; Yolanda Gómez-Gálvez; Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2015-07-31       Impact factor: 8.739

Review 6.  Functional dystonia.

Authors:  D A Schmerler; A J Espay
Journal:  Handb Clin Neurol       Date:  2016

Review 7.  Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….

Authors:  Eric P Baron
Journal:  Headache       Date:  2015-05-25       Impact factor: 5.887

8.  Cannabis sativa and dystonia secondary to Wilson's disease.

Authors:  M Claudia Uribe Roca; Federico Micheli; Ricardo Viotti
Journal:  Mov Disord       Date:  2005-01       Impact factor: 10.338

9.  Medical Cannabis, a Beneficial High in Treatment of Blepharospasm? An Early Observation.

Authors:  Phillip M Radke; Ali Mokhtarzadeh; Michael S Lee; Andrew R Harrison
Journal:  Neuroophthalmology       Date:  2017-07-18

Review 10.  Endocannabinoid signaling at the periphery: 50 years after THC.

Authors:  Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer
Journal:  Trends Pharmacol Sci       Date:  2015-03-18       Impact factor: 14.819

View more
  1 in total

Review 1.  Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.

Authors:  Ian O Bledsoe; Aaron C Viser; Marta San Luciano
Journal:  Neurotherapeutics       Date:  2020-10-23       Impact factor: 7.620

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.